Literature DB >> 11384206

The effect of paracetamol on nociception and dynorphin A levels in the rat brain.

M Sandrini1, P Romualdi, A Capobianco, G Vitale, G Morelli, L A Pini, S Candeletti.   

Abstract

Male Wistar rats were administered with naloxone (1 mg/kg i.p.) or MR 2266 (5 mg/kg i.p) 15 min before paracetamol (400 mg/kg i.p.) treatment and the pain threshold was evaluated. Rats were subjected to the hot-plate and formalin tests and immunoreactive dynorphin A (ir-dynorphin A) levels were measured in the hypothalamus, hippocampus, striatum, brainstem, frontal and parietal-temporal cortex by radioimmunoassay. Pretreatment with naloxone abolished paracetamol antinociceptive activity both in hot-plate and in the first phase, but not in the second phase of the formalin test, while MR 2266 pretreatment was able to antagonise paracetamol effect either in the hot-plate test or in both phases of the formalin test. Among different brain areas investigated paracetamol significantly decreased ir-dynorphin A levels only in the frontal cortex. MR 2266 but not naloxone reversed the decrease in ir-dynorphin A levels elicited by paracetamol. Paracetamol seems to exert its antinociceptive effect also through the opioidergic system modulating dynorphin release in the central nervous system (CNS) of the rat, as suggested by the decrease in the peptide levels. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384206     DOI: 10.1054/npep.2001.0852

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  7 in total

1.  Tolerability and efficacy of a combination of paracetamol and caffeine in the treatment of tension-type headache: a randomised, double-blind, double-dummy, cross-over study versus placebo and naproxen sodium.

Authors:  Luigi Alberto Pini; Enrico Del Bene; Giorgio Zanchin; Paola Sarchielli; Girolamo Di Trapani; Maria Pia Prudenzano; Giovanni LaPegna; Lidia Savi; Giorgio Di Loreto; Paolo Dionisio; Franco Granella
Journal:  J Headache Pain       Date:  2008-09-25       Impact factor: 7.277

Review 2.  The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings.

Authors:  Garry G Graham; Michael J Davies; Richard O Day; Anthoulla Mohamudally; Kieran F Scott
Journal:  Inflammopharmacology       Date:  2013-05-30       Impact factor: 4.473

3.  Effect of resiniferatoxin on the noxious heat threshold temperature in the rat: a novel heat allodynia model sensitive to analgesics.

Authors:  Róbert Almási; Gábor Pethö; Kata Bölcskei; János Szolcsányi
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

4.  Differential involvement of opioidergic and serotonergic systems in the antinociceptive activity of N-arachidonoyl-phenolamine (AM404) in the rat: comparison with paracetamol.

Authors:  Valentina Ruggieri; Giovanni Vitale; Luigi Alberto Pini; Maurizio Sandrini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-04-11       Impact factor: 3.000

5.  Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over study.

Authors:  Luigi Alberto Pini; Simona Guerzoni; Michela Cainazzo; Michela Ciccarese; Maria Pia Prudenzano; Paolo Livrea
Journal:  J Headache Pain       Date:  2012-10-02       Impact factor: 7.277

6.  Roles of opioid receptor subtype in the spinal antinociception of selective cyclooxygenase 2 inhibitor.

Authors:  Cheol Hun Choi; Woong Mo Kim; Hyung Gon Lee; Cheol Won Jeong; Chang Mo Kim; Seong Heon Lee; Myung Ha Yoon
Journal:  Korean J Pain       Date:  2010-12-01

7.  Effect of nonsteroidal anti-inflammatory drugs on colorectal distension-induced visceral pain.

Authors:  Veysel Baskın; S Sırrı Bilge; Ayhan Bozkurt; Bahar Akyüz; Arzu Erdal Ağrı; Hasan Güzel; Fatih İlkaya
Journal:  Indian J Pharmacol       Date:  2016 Mar-Apr       Impact factor: 1.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.